Related Experiment Video

Updated: Jun 10, 2026

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

[Refractory Kawasaki disease with coronary aneurysms treated with infliximab]

J Salas Salguero1, D Gómez-Pastrana Durán, C Salido Peracaula

  • 1Hospital de Jerez, Jerez de la Frontera, Cádiz, España. dr.fjss@gmail.com

Anales De Pediatria (Barcelona, Spain : 2003)
|August 4, 2010
PubMed

Insights

Kawasaki disease treatment with immunoglobulin is effective in most cases. For non-responsive patients, infliximab offers a promising second-line therapy, as shown in a case of refractory Kawasaki disease with coronary aneurysms.

Area of Science:

  • Pediatric Cardiology
  • Immunology
  • Rheumatology

Background:

  • Kawasaki disease is a leading cause of acquired heart disease in children.
  • Standard treatment involves immunoglobulin and aspirin, achieving a 90% response rate.
  • Refractory cases pose a challenge, with unclear optimal second-line therapies.

Observation:

  • A 5-month-old infant presented with refractory Kawasaki disease.
  • The infant developed coronary aneurysms despite initial treatment with two immunoglobulin doses and three corticosteroid pulses.
  • This highlights the need for alternative treatment strategies in non-responsive cases.

Findings:

  • A single dose of infliximab was administered to the infant.
  • The patient showed good clinical progress following infliximab treatment.
  • This suggests infliximab's potential efficacy in severe, refractory Kawasaki disease.

Implications:

  • Infliximab may be a viable and effective second-line treatment for refractory Kawasaki disease.
  • Further research and clinical trials are warranted to establish infliximab's role.
  • This case contributes to the growing evidence supporting infliximab in managing complex Kawasaki disease cases.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...